No coin nor oath required. For personal study only.
the maximum milk concentration was 7.9 ng/mL and the maximum milkto-plasma ratio was 0.025. Caution should be exercised when TORADOUM or R~&& is administered to a nursing woman.
Safety and efficacy in children have not been established. Therefore, TORADOL is not recommended for use in children.
Because ketoro]ac tramethamine is cleared somewhat more slowly by the elderly (sea CLINICAL PHARMACOLOGY section of full prescribing information) who are atso more sensitive to the renal effects of NSAtDs (see PRECAUTIONS --Renal Effects), extra caution and reduced dosages (see DOSAGE AND ADMINISTRATION section of full prescribing information) should be used when treating the elderly with TORADOL.
Adverse reaction rates from short-term use of NSAIDs are generally from 1/10 to 1/2 the rates associated with long-term use. This is also true for TORADOL. Adverse reaction rates also may increase with higher doses of TORADOL (see WARNINGS, and DOSAGE AND ADMINISTRATION section o1 full prescribing information). TORADOU-M is indicated for short-term use. Physicians using TORADOL -M should be alert for the usual complications of NSAID treatment, and should be aware that with longer use (exceeding 5 days) of TORADOU M, the frequency and severity of adverse reactions may increase. Physicians using TORADOLO~aL should be alert to the relative risks associated with dose and dose duration as described in CLINICAL PHARMACOLOGY --Clinical Studies section of full prescribing information. Physicians using TORADOL should be alert for the usual complications o1 NSAID treatment. The adverse reactions listed below were reported in clinical trials with TORADOL in which patients received up to 20 doses, in 5 days, of TORADOU v 30 mg or up to 4 doses a day from long-term studies of TORADOL oRAL 10 mg OlD. In addition, adverse reactions that were reported from TORADOL~. post-marketing surveillance, are included in "Incidence 1% or Less." Incidence Greater than 1% (probably causally related
๐ SIMILAR VOLUMES
The abstracts should be typewritten on 81/2 " x 11" paper, double spaced. Full names, titles, mailing address, and phone number should be given on a separate sheet. Sessions will be devoted to the presentation of selected scientific papers. These papers may cover a range of significant areas of eme
Program Chairman Judith E Tintinalli, MD, is now accepting abstracts for review for presentation at the Annual Meeting. Abstracts must be limited to one 8W'x11" sheet, double-spaced, including tables. No graphs, figures, or illustrations may be submitted as part of one abstract. Results of tests of
Chair of the Educational Meetings Committee, has set July 15, 1991, as the deadline for submission of notice of intent to present an educational/informative exhibit. Educational/informative exhibits may deal with any topic pertinent to emergency medicine. For example, exhibits may display new devel